Cocrystal Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
COCP$1.11+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $15,169 | $12,392 |
| General and administrative | 5,990 | 5,745 |
| Legal settlement | (2,600) | 1,600 |
| Impairments | - | 19,092 |
| Total operating expenses | 18,559 | 38,829 |
| Loss from operations | (18,559) | (38,829) |
| Other (expense) income: | ||
| Interest income (expense), net | 640 | (2) |
| Change in fair value of derivative liabilities | - | 12 |
| Foreign exchange loss | (65) | (18) |
| Total other income (expense), net | 575 | (8) |
| Net loss | $(17,984) | $(38,837) |
| Net loss per common share: | ||
| Loss per share, basic and diluted | $(1.87) | $(4.77) |
| Weighted average number of common shares outstanding, basic and diluted | 9,651 | 8,143 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.